Bjekić-Macut, Jelica (54400683700)Jelica (54400683700)Bjekić-MacutŽivković, Teodora Beljić (18635730200)Teodora Beljić (18635730200)ŽivkovićKocić, Radivoj (6507102616)Radivoj (6507102616)Kocić2025-06-122025-06-122018https://doi.org/10.1007/s13300-018-0406-4https://www.scopus.com/inward/record.uri?eid=2-s2.0-85044509502&doi=10.1007%2fs13300-018-0406-4&partnerID=40&md5=23e7ef34b1db1d053d12957066588289https://remedy.med.bg.ac.rs/handle/123456789/6370In the original publication, values of the doses of insulin glargine, the most commonly used basal insulin analogue under the ‘Discussion’ section was incorrectly published. The sentence ‘‘…was similar (3100.314 ± 110.1298 U/kg body weight/day at baseline) to that in the Swedish study (0.33 ± 0.16 U/kg body weight/day)’’. Should actually say ‘‘…was similar (0.31 ± 0.12 U/kg body weight/day at baseline) to that in the Swedish study (0.33 ± 0.16 U/kg body weight/day)’’. Open Access. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/ by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. © 2018, The Author(s).Erratum to: Clinical Benefit of Basal Insulin Analogue Treatment in Persons with Type 2 Diabetes Inadequately Controlled on Prior Insulin Therapy: A Prospective, Noninterventional, Multicenter Study (Diabetes Therapy, (2018), 10.1007/s13300-018-0378-4)